No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers

Journal of Clinical Pharmacology

Volumn 52, Issue 11, 2012, Pages 1739-1748

  Cawello, Willi ^a   Bonn, Rainer ^a  

^a UCB PHARMA   (Belgium)

Author keywords

drug drug interaction; Lacosamide; pharmacokinetics; valproic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUTAMATE DEHYDROGENASE; HARKOSERIDE; LIVER ENZYME; VALPROIC ACID;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ATRIOVENTRICULAR BLOCK; BACKACHE; BIOEQUIVALENCE; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ECG ABNORMALITY; EYE TOXICITY; FATIGUE; GINGIVA BLEEDING; HEADACHE; HEART RATE; HOT FLUSH; HUMAN; HYPERTENSION; HYPESTHESIA; LYMPHADENOPATHY; MALE; MENTAL CONCENTRATION; MORNING DOSAGE; NAUSEA; NORMAL HUMAN; PAIN; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TOXICITY; SYSTOLIC BLOOD PRESSURE; VOMITING;

ACETAMIDES; ADULT; ANTICONVULSANTS; AREA UNDER CURVE; DRUG INTERACTIONS; HUMANS; MALE; VALPROIC ACID; YOUNG ADULT;

EID: 84861727071     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011426875     Document Type: Article

References (23)

1. Patsalos PN, Froscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002 ; 43: 365-385 (Pubitemid 34297175)
2. French JA, Faught E. Rational polytherapy. Epilepsia. 2009 ; 50: 63-68
3. Kwan P, Brodie MJ. Combination therapy in epilepsy: when and what to use. Drugs. 2006 ; 66: 1817-1829 (Pubitemid 44584005)
4. Ben-Menachem E. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today (Barc). 2008 ; 44: 35-40 (Pubitemid 351397411)
5. Doty P, Rudd GD, Stoehr T, Thomas D. Lacosamide. Neurotherapeutics. 2007 ; 4: 145-148 (Pubitemid 46107317)
6. Beyreuther BK, Freitag J, Heers C, Krebsfanger N, Scharfenecker U, Stohr T. Lacosamide: a review of preclinical properties. CNS Drug Rev. 2007 ; 13: 21-42 (Pubitemid 46697839)
7. Brussels, Belgium: UCB Pharma S.A. ; 2008 :
8. Cawello W, Kropeit D, Schiltmeyer B, Hammes W, Horstmann R. Food does not affect the pharmacokinetics of SPM 927 [abstract]. Epilepsia. 2004 ; 45: 307
9. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 2002 ; 51: 31-71 (Pubitemid 35283878)
10. Beydoun A, D'Souza J, Hebert D, Doty P. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother. 2009 ; 9: 33-42
11. Patsalos PN. Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia. 2005 ; 46: 140-148 (Pubitemid 44921992)
12. Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci. 2006 ; 94: 261-271 (Pubitemid 44817142)
13. Chicago: Abbott Laboratories ; 2009 :
14. Cawello W, Nickel B, Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol. 2010 ; 50: 459-471
15. Horstmann R, Bonn R, Cawello W, Doty P, Rudd GD. SPM 927 does not interact with valproic acid and carbamazepine [abstract]. Epilepsia. 2003 ; 44: 97
16. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. London: European Agency for the Evaluation of Medicinal Products ; 2001 :
17. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008 ; 49: 1239-1276 (Pubitemid 351991390)
18. Gugler R, von Unruh GE. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet. 1980 ; 5: 67-83 (Pubitemid 11192690)
19. Horstmann R, Bonn R, Cawello W, Doty P, Rudd GD. Basic clinical pharmacologic investigations of the new antiepileptic drug SPM 927 [abstract]. Epilepsia. 2002 ; 43: 188
20. A.D.A.M., Inc. Therapeutic drug levels. In: A.D.A.M. Medical Encyclopedia. Atlanta, GA: A.D.A.M., Inc; 2005. http://www.nlm.nih.gov/ medlineplus/ency/article/003430.htm
21. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007 ; 48: 1308-1317 (Pubitemid 47063096)
22. Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009 ; 50: 443-453
23. Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010 ; 51: 958-967